An optimized PanFlu-IOA-based mRNA vaccine targeting hemagglutinin confers broad-spectrum protection against heterosubtypic influenza viruses in mice
In the authors' words
The rapid mutation rate of influenza viruses necessitates annual updates of vaccine formulations, underscoring the urgent need for a universal influenza vaccine. Current computationally optimized antigen strategies are mostly confined to certain subtypes and thus fail to elicit broad-spectrum immunity against heterosubtypic strains. Here, we developed the PanFlu-IOA (Pan-Influenza Iteratively Optimized Antigen) toolkit to overcome systemic bias and extract universal antigenic features across diverse evolutionary branches. Using this toolkit, we generated two universal hemagglutinin (HA) sequences G1-HA and G2-HA for influenza virus Group 1 and Group 2, respectively. These two HAs were incorporated into an mRNA-lipid nanoparticle system to construct a broad-spectrum vaccine candidate termed panFluA. In mice, panFluA elicits robust cross-reactive humoral immunity, Th1-biased systemic CD4⁺ T cell responses, and cytotoxic CD8⁺ T cell activation, while successfully establishing durable lung-resident memory T cells. Notably, panFluA conferred potent cross-protection against lethal challenges with highly divergent Group 1 and Group 2 influenza viruses. Mechanistic studies revealed that this protection was mediated by the coordinated action of humoral and cellular immunity, as confirmed by T-cell depletion and passive serum transfer experiments. Overall, panFluA induced broad immune responses against conserved HA antigens. Our study provides a general strategy for next-generation universal influlenza vaccines. Researchers developed PanFlu-IOA, a computational approach to design a broad spectrum mRNA influenza vaccine. The vaccine induced broad immune responses and protected mice against multiple influenza subtypes, offering a path to universal vaccines.
Appeared: Tuesday, November 17. Nature Communications. Peer-reviewed journal.